Add BrightSurf on Google Email

Diabetes drug could help cancer patients make better recovery

A new study published in the European Journal of Preventive Cardiology found that a type of diabetes medication called SGLT2 inhibitors can significantly lower the risk of heart failure and hospital visits related to heart failure in cancer patients. The benefits were particularly promising for breast cancer patients receiving anthracy...

SourceUniversity of East Anglia·JournalEuropean Journal of Preventive Cardiology·TypeMeta-analysis·DateMar 5, 2025

ASTRO issues its first clinical guideline on radiation therapy for anal cancer

The American Society for Radiation Oncology (ASTRO) has published its first clinical guideline on radiation therapy for anal cancer, providing guidance on treatment options and techniques. The guideline recommends a combination of radiation therapy and drug therapy as the standard of care, with intensity-modulated radiation therapy (IM...

SourceAmerican Society for Radiation Oncology·JournalPractical Radiation Oncology·DateFeb 27, 2025

A protein from tiny tardigrades may help cancer patients tolerate radiation therapy

Researchers have developed a new strategy to protect cancer patients from radiation-induced DNA damage using a protein from tardigrades. The approach makes use of messenger RNA encoding the protein, which is delivered to patient tissues before radiation treatment. This reduces double-stranded DNA breaks by 50% in mouse models.

SourceMassachusetts Institute of Technology·JournalNature Biomedical Engineering·DateFeb 26, 2025

Breast-conserving surgery improves sexual well-being compared to breast reconstruction

A study published in Plastic and Reconstructive Surgery reports that women who undergo breast-conserving therapy (BCT) experience improved sexual well-being compared to those who receive post-mastectomy breast reconstruction (PMBR). Scores on a sexual well-being subscale were consistently higher for BCT patients, with average scores 7....

SourceWolters Kluwer Health·JournalPlastic & Reconstructive Surgery·DateFeb 26, 2025

Morphomic predictors for post-esophagectomy pulmonary complications and overall survival

Increased visceral adipose tissue density and decreased skeletal muscle area are predictors of post-esophagectomy pulmonary complications. Decreased skeletal muscle density is associated with poorer overall survival. Routine morphomic analysis can help identify patients at risk and tailor perioperative care.

SourceNational Center for Respiratory Medicine·JournalJournal of Thoracic Disease·TypeObservational study·DateFeb 25, 2025

Lancet article details drug’s lack of benefit for head and neck cancer

A recent Lancet article revealed that durvalumab combined with radiation therapy offers no benefits for patients with head and neck cancer who cannot receive cisplatin. However, a new clinical trial is underway to test the use of a heavy metal to enhance radiation therapy, providing potential new options for these patients.

SourceUniversity of Oklahoma·JournalThe Lancet·TypeRandomized controlled/clinical trial·DateFeb 20, 2025

New study suggests panitumumab with low-dose capecitabine as a safer, effective maintenance treatment for advanced colorectal cancer

Researchers found that a combination of Panitumumab and low-dose Capecitabine is an effective and well-tolerated maintenance regimen for patients with wild-type KRAS metastatic colorectal cancer. The treatment delayed disease progression while managing side effects, improving patients' quality of life.

SourceImpact Journals LLC·JournalOncotarget·TypeNews article·DateFeb 18, 2025

Electronic reporting of symptoms by cancer patients can improve quality of life and reduce emergency visits

A multicenter study found that electronic symptom monitoring improved quality of life, clinical outcomes, and well-being in metastatic cancer patients. The PRO-TECT trial showed significant benefits for patients who reported their symptoms via a home-based electronic monitoring system.

SourceUniversity of North Carolina Health Care·JournalNature Medicine·TypeRandomized controlled/clinical trial·DateFeb 7, 2025

Building better biomaterials for cancer treatments

A Virginia Tech research team has made significant progress in understanding the role of physical properties in tuning the body's immune responses. By modifying biomaterials' size, shape, and stiffness, they aim to enhance immune cell behavior and stimulate antitumor immune responses.

SourceVirginia Tech·JournalJournal of Controlled Release·TypeLiterature review·DateFeb 6, 2025

Cancer vaccine shows promise for patients with stage III and IV kidney cancer

A phase 1 trial of a personalized cancer vaccine for patients with stage III or IV clear cell renal cell carcinoma showed a positive response in all nine patients, with no higher-grade side effects reported. The vaccine generated a successful anti-cancer immune response and kept patients cancer-free at the time of data cut-off.

SourceDana-Farber Cancer Institute·JournalNature·TypeRandomized controlled/clinical trial·DateFeb 5, 2025

Patient advocates from NCCN guidelines panels share their ‘united by unique’ stories for world cancer day

The National Comprehensive Cancer Network is joining the global effort to improve awareness and knowledge of cancer risks through its 'United by Unique' campaign. Patient advocates from NCCN guidelines panels are sharing their personal stories to highlight the importance of a people-centered approach in cancer care, which recognizes ev...

CNIC scientists design an effective treatment strategy to prevent heart injury caused by a class of anticancer drugs

Researchers at the CNIC have designed a treatment strategy to protect the heart against cardiotoxic effects of anthracyclines, a common class of anticancer drugs. Empagliflozin, an SGLT2 inhibitor, has been shown to preserve cardiac function and metabolism in experimental models.

SourceCentro Nacional de Investigaciones Cardiovasculares Carlos III (F.S.P.)·JournalJACC CardioOncology·TypeExperimental study·DateFeb 4, 2025

Study shows high-precision radiation therapy is safe for patients with cancer that has spread throughout body

A new Phase I clinical trial from London Health Sciences Centre Research Institute found high-precision radiation therapy to be safe in treating patients with polymetastatic disease. The study, known as ARREST, used stereotactic ablative radiotherapy (SABR) to treat cancer that has spread to more than 10 spots in the body.

SourceLondon Health Sciences Centre Research Institute·JournalInternational Journal of Radiation Oncology*Biology*Physics·TypeRandomized controlled/clinical trial·DateFeb 3, 2025

UCLA-led study establishes link between early side effects from prostate cancer radiation and long-term side effects

A recent study published in Lancet Oncology reveals a significant link between early side effects from radiation therapy for prostate cancer and long-term complications. Men who experience moderate acute urinary or bowel side effects during treatment are nearly twice as likely to develop late urinary or bowel issues, respectively. This...

In HER2+ colorectal cancer, anti-HER2 therapy may be less toxic alternative

A phase 2 clinical trial found that a combination of two HER2 inhibitors was more effective and better tolerated than standard EGFR inhibitor-based therapy for patients with HER2-positive metastatic colorectal cancer. The study showed that the level of HER2 amplification in tumors played a key role in determining treatment outcomes.

SourceSWOG Cancer Research Network·JournalJournal of Clinical Oncology·TypeRandomized controlled/clinical trial·DateJan 29, 2025

Nourishing T cells to fight cancer

Researchers at the University of Pittsburgh have developed a new way to grow T cells that can live longer and better destroy cancer cells in mice. By adding a compound called dichloroacetate to growth media, they created T cells less reliant on glucose and more efficient at using other energy sources.

SourceUniversity of Pittsburgh·JournalCell Metabolism·DateJan 28, 2025

Cancer drugs linked to severe chronic peripheral nerve pain for 4 in every 10 patients

A pooled data analysis found that cancer chemotherapy is linked to persistent severe peripheral nerve pain for around 4 in every 10 patients, with platinum-based drugs and taxanes associated with the highest rates of painful neuropathy. The study analyzed data from 77 eligible studies involving 10,962 participants from 28 countries.

SourceBMJ Group·JournalRegional Anesthesia & Pain Medicine·TypeObservational study·DateJan 28, 2025